Twenty-nine advanced breast cancer patients, considered unable to tolerate conventional cytotoxic chemotherapy, were treated with a weekly schedule of epirubicin (15 mg/m2 i.v.). All patients were fully evaluable. A remission of 34.5 % was observed (2 CR; 8 PR), with a median duration of response of 9 months (range, 3–24 months). Side effects were mild, and on the whole the toxicity was negligible. This regimen showed a favorable therapeutic ratio in our series and seems active and well tolerated even in elderly and/or poor performance status patients.
Get full access to this article
View all access options for this article.
References
1.
BerettaG., LocatelliD., TabiadonD., LabiancaR., FraschiniP., LuporiniG.: Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen.Oncology, 44: 6–12, 1987.
2.
CersosimoR.J., HongW.K.: Epirubicin: A review of the pharmacology, clinical activity and adverse effects of an adriamycin analogue.J. Clin. Oncol., 4: 425–439, 1986.
3.
GuarnieriA., TucciE., PepiF., D'AnielloC., BastreghiG., CarliA., BindiM., PirtoliL.: Associazione di epirubicina e vincristina (EV) nel trattamento del carcinoma mammario metastatico.Atti V Riun. Naz. Onc. Sper. Clin., Abs. 161, p. 101, Ancona, 1987.
4.
JonesW.G., MattssonW.: Phase II study of weekly low-dose 4′-epidoxorubicin in advanced postmenopausal breast cancer.Cancer Treat. Rep., 68: 675–677, 1984.
5.
JonesW.G.: Weekly low-dose epirubicin: effective single agent palliation for advanced breast cancer.Proc. 4th E.O.R.T.C. Breast Cancer Working Conference, Abst. F 2.3, London, 1987.
6.
LombardiF., FaccendiniE., RinaldiE., LanzettiV., MereghettiM., NegrettiS., BiasioliR.: Epirubicina settimanale nel trattamento del carcinoma mammario avanzato.Atti IV Riun. Naz. Onc. Sper. Clin., Abst. 246, p. 714, Bari, 1986.
7.
MattssonW., BörgstromS., LandbergT.: A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer.Clin. Ther., 5: 193–203, 1982.
8.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
9.
ScheulenM.E., KiederleM., DoberauerC., HöffkenK., SchmidtC.G.: Low-dose weekly treatment of metastatic breast cancer with 4′-epi-doxorubicin (epirubicin).Proc. 14th Int. Cancer Congress, Abst. 3814, p. 191, Budapest, 1986.
10.
SigurdssonH., Johansson-TerseI., AspegrenK., LandbergT., AnderssonT., BorgströmS., ThelinA.M.: Weekly-dose doxorubicin (WDA) in advanced breast cancer.Radiother. Oncol., 7: 133–139, 1986.
11.
TabiadonD., BerettaG., LocatelliM.C., D'AntonaA., GambrosierP., LuporiniG.: Epirubicina settimanale nel carcinoma mammario avanzato.Atti II Riun. Naz. Onc. Sper. Clin., Abst. 120, p. 116, Abano Terme, 1984.
